The robustness of business strategies are reviewed by the management at regular intervals. The business plans are modified and improvements made as an ongoing process.
The medium term strategy of World Medicine is to continuously globalise the intellectual property assets and enhance value to shareholders and customers.
In global markets, the Company shall retain and enhance cost efficient quality leadership in broad spectrum of quality and lifestyle disease drugs. It is the endeavour of the company to achieve this by improving process efficiencies, adopting global scale manufacturing and using cost effective market networks throughout North and South America, Europe, Asia, Middle and Far East and Africa.
World Medicine shall repeat its success and emerge as a major player in countries of presence while planning to obtain regulatory approvals for registration of novel pharmaceuticals in lifestyle disease drugs and sterile and non-sterile cephalosporins having substantial entry barriers.
The Company’s competitive advantage is in capturing a large portfolio of approvals, backed up by a global standard R&D effort that offers several patented non-infringing processes and intellectual properties, and a cost efficient mega manufacturing network complying to US FDA and EU authorities.
The corporate plans are to ensure growth through organic means, and by adopting strategic joint ventures and alliances. The objective is to maximize the revenues and reduce risks.